Gadodiamide

Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.

Gadodiamide
Clinical data
Other names2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate; gadolinium(+3) cation
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingnegligible
Metabolismnot metabolized
Elimination half-life77.8 minutes
ExcretionKidney
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H28GdN5O9
Molar mass591.68 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Uses

A bottle of Omniscan contrast agent.

Gadodiamide is a drug i.e contrast medium used for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). It does not cross an intact blood brain barrier but might give enhancement in pathological conditions.

Adverse effects

It has been associated with a toxic reaction known as nephrogenic systemic fibrosis (NSF) in some people with severe kidney problems.[2] No cases have been seen in people with normal kidney function.[3]

A 2015 study found trace amounts of gadolinium deposited in the brain tissue of people that had received gadodiamide.[4] This is of unknown significance.[4]

In the United States there are recommendations that one does not need to stop or altering breastfeeding while in Europe it is recommended that a mother throw out 24 hours of breast milk.[5]

References

  1. https://www.ema.europa.eu/documents/psusa/gadodiamide-list-nationally-authorised-medicinal-products-psusa/00001503/202004_en.pdf
  2. Ibrahim MA, Hazhirkarzar B, Dublin AB (January 2018). "Magnetic Resonance Imaging (MRI), Gadolinium". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29494094.
  3. Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P (2008). "Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness". Journal of Nephrology. 21 (3): 324–36. PMID 18587720.
  4. Anderson P (2015-03-26). "Gadolinium Found in Brain Tissue". Medscape. Retrieved 14 April 2015.
  5. "Gadodiamide". Drugs and Lactation Database. 2006. PMID 30000472.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.